<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONRC-13003482</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2013-04-24</date_registration>
      <primary_sponsor>The First Affiliated Hospital of Zhejiang University</primary_sponsor>
      <public_title>The effect and safety of high-dose chemotherapy combined with allogeneic hematopoietic stem cell enfusion in patients with relapsed / refractory acute myeloid leukemia</public_title>
      <acronym />
      <scientific_title>The effect and safety of high-dose chemotherapy combined with allogeneic hematopoietic stem cell enfusion in patients with relapsed / refractory acute myeloid leukemia</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2013-09-01</date_enrolment>
      <type_enrolment />
      <target_size>Group of stem cell infusion:30;Group of chemotherapy:30;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=6078</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>Other</phase>
      <hc_freetext>acute myeloid leukemia</hc_freetext>
      <i_freetext>Group of stem cell infusion:Chemotherapy+stem cell infusion;Group of chemotherapy:Chemotherapy 	;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Jingsong He</firstname>
        <middlename />
        <lastname />
        <address>Building 2, 10th Floor,  79 Qingchun Road, Hangzhou, Zhejiang, China</address>
        <city />
        <country1 />
        <zip>310003</zip>
        <telephone>+86 13600547247</telephone>
        <email>hjs2005@263.net</email>
        <affiliation>The First Affiliated Hospital of Zhejiang University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>He Huang</firstname>
        <middlename />
        <lastname />
        <address>Building 2, 10th Floor,  79 Qingchun Road, Hangzhou, Zhejiang, China</address>
        <city />
        <country1 />
        <zip>310003</zip>
        <telephone>+86 571 87236703</telephone>
        <email>hehuangyu@126.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2 />
    </countries>
    <criteria>
      <inclusion_criteria>1. Subjects or their legal representatives should signed informed consent;
2. Male or non-pregnant female;
3. Subjects must younger than 60, and the expected survival is 3 months or more;
4. The score of ECOG physical status must be 0 to 2;
5. The laboratory values should be (unless caused by the leukemia): creatinine clearance &gt;=50mL/min, or serum  creatinine &lt;=1.5mg/dl, and bilirubin &lt;=2 times the upper limit of normal;
6. Subjects must have been restored to &lt;=1 degree of all non-hematologic toxicity (NCI CTC AE3.0 Edition)     which have been from the previous treatment;
7. Subjects were diagnosed of relapsed / refractory acute myeloid leukemia patients, according to FAB, or WHO  diagnostic criteria.</inclusion_criteria>
      <agemin>14</agemin>
      <agemax>59</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. The patients were diagnosed of acute lymphoblastic leukemia, or acute mixed cell leukemia, or acute promyelocytic leukemia;
2. The patients have been used FLAG regimen, and clearly ineffective;
3. The patients with severe liver, kidney, or cardiopulmonary dysfunction;
4. The patients had uncontrolled or severe heart disease or infection, or mental illness;
5. The patients had received allogeneic hematopoietic stem cell transplantation;
6. The patients had other malignancies(unless the patients have completed treatment and doctors believe        impossible relapse within 1 year).</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Complete remission rate;Overall response rate ;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Safety;Disease free survival;Progression-free survival;Overall survival;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self-financing</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-06-28</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>